Ekso Bionics Holdings Stock Today
| EKSO Stock | USD 0.57 0.01 1.79% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Ekso Bionics is selling at 0.57 as of the 16th of February 2025; that is 1.79 percent increase since the beginning of the trading day. The stock's open price was 0.56. Ekso Bionics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 16th of January 2014 | Category Healthcare | Classification Health Care |
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company was incorporated in 2005 and is headquartered in Richmond, California. The company has 22 M outstanding shares of which 1.12 M shares are currently shorted by private and institutional investors with about 0.39 trading days to cover. More on Ekso Bionics Holdings
Moving against Ekso Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ekso Stock Highlights
| Chairman of the Board | Steven Sherman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Machinery (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Machinery, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEkso Bionics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ekso Bionics' financial leverage. It provides some insight into what part of Ekso Bionics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ekso Bionics Holdings (EKSO) is traded on NASDAQ Exchange in USA. It is located in 101 Glacier Point, San Rafael, CA, United States, 94901 and employs 70 people. Ekso Bionics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.55 M. Ekso Bionics Holdings conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 22 M outstanding shares of which 1.12 M shares are currently shorted by private and institutional investors with about 0.39 trading days to cover.
Ekso Bionics Holdings currently holds about 31.91 M in cash with (12.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Ekso Bionics Probability Of Bankruptcy
Ownership AllocationEkso Bionics holds a total of 22 Million outstanding shares. Ekso Bionics Holdings shows 7.91 percent of its outstanding shares held by insiders and 19.33 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Ekso Ownership Details
Ekso Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Consolidated Portfolio Review Corp. | 2024-12-31 | 10.2 K | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 3.1 K | |
| Tower Research Capital Llc | 2024-09-30 | 1.1 K | |
| Harbour Investments, Inc. | 2024-09-30 | 458 | |
| Tradewinds Capital Management, Llc | 2024-12-31 | 260 | |
| Bank Of America Corp | 2024-09-30 | 246 | |
| Goss Wealth Management Llc | 2024-09-30 | 200 | |
| Ubs Group Ag | 2024-09-30 | 148 | |
| Jpmorgan Chase & Co | 2024-09-30 | 90.0 | |
| Armistice Capital, Llc | 2024-09-30 | 2.2 M | |
| Vanguard Group Inc | 2024-09-30 | 594.4 K |
Ekso Bionics Historical Income Statement
Ekso Stock Against Markets
Ekso Bionics Corporate Management
| Stephan Aderhold | Senior EMEA | Profile | |
| Rachael Anderson | Global Growth | Profile | |
| Scott Davis | Chief Officer | Profile | |
| Katherine Strausser | Principal Engineer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.